Want to see GB:CTEC full AI Analyst Report?
CTEC Stock Chart & Stats
216.00 p
4.20 p(1.94%)
At close: 4:00 PM EDT
216.00 p
4.20 p(1.94%)
Day’s Range― - ―
52-Week Range193.00 p - 259.30 p
Previous CloseN/A
Volume4.45M
Average Volume (3M)6.27M
Market Cap
£4.37B
Enterprise Value6.06K
Total Cash (Recent Filing)£75.03M
Total Debt (Recent Filing)£1.52B
Price to Earnings (P/E)34.5
Beta1.13
Next Earnings
Aug 04, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield2.4%
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,954,852,000
10 Day Avg. Volume5,278,857
30 Day Avg. Volume6,266,139
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£298.17Price Target Upside38.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.2
Revenue Forecast (FY)£2.56B
Bulls Say, Bears Say
Bulls Say
Consistent Organic Revenue GrowthSustained mid-single-digit organic growth across five years and management guidance (5–7% ex-InnovaMatrix, medium-term 6–8%) indicate durable end-market demand for chronic-care consumables, supporting stable top-line expansion driven by recurring use, reimbursement, and product rollouts over the next 2–6 months and beyond.
Margin Expansion And GuidanceMeaningful operating margin improvement (+110 bps in 2025, +460 bps since 2021) reflects structural gains from pricing, productivity and mix shifts (Infusion/advanced products). Management’s mid‑20s margin target suggests sustainable operating leverage as launches scale and cost programs persist over the medium term.
Strong Cash Generation And Capital ReturnsRobust operating cash flow and near-100% free-cash conversion provide durable financial flexibility: funds internal investment for growth CapEx, steady dividends and buybacks. This cash profile supports capacity buildouts and shareholder returns while de-risking execution over multiple quarters.
Bears Say
Increased LeverageHigher leverage reduces financial flexibility and raises interest-rate sensitivity as the company increases growth CapEx. With management targeting ~2x net debt/EBITDA, the balance sheet is more dependent on continued cash generation and execution to avoid constraints on M&A, buybacks or cushioning against shocks.
Regulatory/QC Process Risk (FDA Warning)An FDA warning on complaints/CAPA processes is a persistent operational and compliance risk; remediation can take months, may constrain U.S. market access, invite increased scrutiny, raise inspection frequency or slow product launches, all of which can structurally hamper growth and margin realization.
Reimbursement-driven Product Shock (InnovaMatrix)A severe CMS price reduction that drove a material impairment highlights the company’s exposure to reimbursement policy. Such reimbursement shocks can sharply curtail revenue and profitability in affected product lines and create channel/legal uncertainty, making recovery and forecasting for that business uncertain.
ConvaTec News
CTEC FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest share price was 193.00 p and its highest was 259.30 p in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is £4.37B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 2 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported 0.072 p earnings per share for the quarter, missing the consensus estimate of 0.074 p by -0.002 p.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec pays a Semiannually dividend of 3.973 p which represents an annual dividend yield of 2.4%. See more information on ConvaTec dividends here
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.06.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of 0.072 p in its last earnings report, missing expectations of 0.074 p. Following the earnings report the stock price went up 10.397%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in GB:CTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£298.17 (38.04% Upside)
£298.17 (38.04% Upside)
Insider Transactions
Bought Shares
Worth £150.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.61%
12-Months-Change
Fundamentals
Return on Equity
2.40%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
CTEC Stock 12 Month Forecast
Average Price Target
298.17 p
▲(38.04% Upside)






